Clinical Studies Sponsored by Intercept Pharmaceuticals

Clinical Studies Sponsored by Intercept Pharmaceuticals

Clinical Studies Sponsored by Jagiellonian University

Clinical Studies Sponsored by University of California, Berkeley

Clinical Studies Sponsored by Fate Therapeutics

List of awards received by Kolchak, Alexander Vasilyevich

Companies in the Tea industry

Clinical Studies where

Trial Sponsor

is

	Name	Description	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
	‌ Study of INT-747 in Patients With Diabetes and Presumed NAFLD		NCT00501592	Fatty liver	2007	2009	Interventional
	‌ Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)		NCT00550862		2007	2010	Interventional
	‌ Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)		NCT01933503	‌ Healthy	2013	2013	Interventional
	‌ Hepatic Impairment Trial of Obeticholic Acid		NCT01904539		2013	2013	Interventional
	‌ Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment		NCT03633227		June 22, 2018	July 9, 2021	Interventional
	‌ Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC		NCT05239468	Primary biliary cholangitis	March 21, 2022	2024	Interventional
	‌ Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)		NCT02177136		February 9, 2015	March 22, 2018	Interventional
	‌ Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients		NCT05292872	Primary biliary cholangitis	March 28, 2022	July 15, 2022	Observational
	‌ Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)		NCT00570765		January 17, 2008	September 25, 2017	Interventional
	‌ Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis		NCT01473524		2012	December 17, 2018	Interventional
	‌ Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)		NCT02633956		December 4, 2015	March 12, 2018	Interventional
	‌ FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study		NCT05639543		December 15, 2022	December 31, 2024	Interventional
	‌ Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC		NCT04594694	Primary biliary cholangitis	October 2, 2019	2024	Interventional
	‌ Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis		NCT01865812		December 3, 2013	September 12, 2016	Interventional

14 results

0 selected

14 results

0 selected